Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial Southampton, UK – 20 October...

Synairgen plc - Interim results for the six months ended 30 June 2020 Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2020 Southampton, UK – 29 September 2020: Synairgen plc (LSE: SNG), the respiratory drug...

Synairgen Completes Recruitment of Hospitalised Patients in COVID-19 Trial Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen Completes Recruitment of Hospitalised Patients in COVID-19 Trial Southampton, UK – 28 May 2020: Synairgen plc (LSE: SNG), the...